|国家科技期刊平台
首页|期刊导航|中国医学伦理学|去中心化临床试验的挑战、对策及伦理审查要点

去中心化临床试验的挑战、对策及伦理审查要点OA北大核心CSTPCD

Challenges,countermeasures and key points of ethical review for decentralized clinical trials

中文摘要英文摘要

去中心化临床试验正给临床试验带来新的变革,必须坚持以患者为中心的核心理念,充分保障研究参与者的安全和权益.去中心化临床试验与传统临床试验有相同之处,但去中心化临床试验并不适合所有临床试验,更适用于口服给药、研究参与者病情稳定、疗程较长的临床试验.必须根据临床试验的特点选用去中心化临床试验元素,并在改善研究参与者的获得感、安全、权益和尊严与收集的数据质量之间取得平衡.当前中国去中心化临床试验面临诸多挑战,为积极推进中国去中心化临床试验,应完善监管法规和指导原则,基于以患者为中心的设计原则,首次讨论需实时在线交流,研究者提供更多临床试验服务,风险控制和医疗援助的可及性,使用第三方便捷支付,确保公平招募研究参与者,考虑依从性,数字健康技术的验证,远程监查和电子知情同意合规化,确保收集、传送和分析数据的安全性,以及加强多方培训.伦理审查是保护研究参与者安全和权益的重要手段之一,伦理委员会应关注符合以患者为中心的恰当去中心化临床试验元素,电子知情同意的合规、有效,安全性信息处理与报告,数据收集的隐私保护,远程监查的合规性,家庭健康随访,生物样本管理,试验性医疗产品的管理,以及培训计划.与传统临床试验的互补与结合将使去中心化临床试验元素更容易、更顺利地落地.去中心化临床试验借助科技进步力量,将助推中国药物和医疗器械研发的速度,增强国际竞争力,造福更多患者.

Decentralized clinical trials(DCT)are bringing new changes to clinical trials,the core concept of"patient-centered"must be adhered,and the safety and rights of research participants must be adequately safeguarded.Although DCTs have similarities with traditional clinical trials,they are not suitable for all clinical trials,and are more suitable for oral administration,stable condition of study participants,and longer duration of treatment in clinical trials.DCT,elements must be selected based on the characteristics of clinical trials,and strike a balance between improving the sense of gain,safety,and rights and dignity of research participants,as well as the quality of data collected.Currently,DCT in China face many challenges.To actively promote DCTs in China,regulatory regulations and guiding principles should be improved.Based on patient-centered design principles,the first discussion requires real-time online communication.Researchers should provide more clinical trial services,improve risk control and accessibility of medical assistance,use third-party convenient payments,ensure fair recruitment of research participants,consider compliance,validate digital health technology,remote monitoring and electronic informed consent compliance,ensure the security of data collection,transmission,and analysis,as well as strengthen multi-party training.Ethical review is one of the important means to protect the safety and rights of research participants.Ethics committees should focus on appropriate DCTs elements that are patient-centered,compliance and effectiveness of electronic informed consent,processing and reporting of security information,privacy protection of data collection,compliance of remote monitoring,family health follow-up,management of biological samples and experimental medical products,and training programs.The author believed that the complementarity and combination with traditional clinical trials will make DCTs elements implemented more easily and smoothly.By leveraging the power of scientific and technological advances,DCTs will boost the speed of China's drug and medical device research and development,enhance international competitiveness,and benefit more patients.

卜丽娟;江柯萱;周吉银

山东大学齐鲁医院科研处,山东 济南 250012中国人民解放军陆军第八十集团军医院卫勤,山东 潍坊 261042陆军军医大学第二附属医院临床医学研究中心,重庆 400037

去中心化临床试验以患者为中心伦理审查数字健康技术

decentralized clinical trialpatient-centeredethical reviewdigital health technology

《中国医学伦理学》 2024 (004)

399-407 / 9

2022年陆军军医大学人文社会科学基金重点项目"我市涉及人的健康相关研究伦理治理的现状与对策研究"(2022XRW02);2020年度教育部人文社会科学研究青年项目"医患之间的心理授权及其对医患关系的影响研究"(20YJC840001)

10.12026/j.issn.1001-8565.2024.04.04

评论